Ebola Update: Funding, Vaccines, and More Deaths in DRC

A total of 27 people have died since April, but new funds and the deployment of an experimental vaccine are expected to help contain the virus.

Written byCatherine Offord
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

World Health Organization workers deployed medical kits in response to reports of Ebola cases in DRC in 2017.FLICKR, MONUSCOThe US government has committed another $7 million in funds to fighting Ebola in Democratic Republic of Congo, bringing its total contribution to $8 million, according to a press statement yesterday (May 22) by US Secretary of Health and Human Services, Alex Azar. The announcement comes amid reports of another two deaths from the virus in an outbreak that has killed 27 people since April, prompting the first deployment of an experimental vaccine in the region this week.

“The risk of spreading within the country and to neighboring nations remains real,” Fatoumata Nafo-Traoré of the International Federation of Red Cross and Red Crescent Societies tells Reuters. “One of the lessons we learned in our response to other deadly Ebola outbreaks is that complacency can kill.”

Health authorities were widely criticized for failing to respond more quickly to the outbreak of Ebola in West Africa, which claimed more than 11,000 lives between 2013 and 2016. A much faster response to news of eight confirmed cases and four deaths in Democratic Republic of Congo (DRC) early last year resulted in the World Health Organization (WHO) declaring that outbreak over within a few months.

Cases began reappearing in DRC in the rural town of Bikoro earlier ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies